title: Ciclopirox nail lacquer solution 8% in the 21st century.
abstract: Ciclopirox nail lacquer solution 8% has been shown to be effective in the treatment of dermatophyte onychomycosis of mild to moderate severity Other studies report the effectiveness of ciclopirox nail lacquer in onychomycosis caused by Candida sp and nondermatophyte molds. Ciclopirox nail lacquer may also be valuable in the treatment of early cases of reinfection/relapse. Ciclopirox nail lacquer solution 8% may be an important adjunct to oral antifungal therapy in certain presentations that might be poorly responsive to oral antifungal therapy alone (eg, lateral onychomycosis, longitudinal spike, dermatophytoma, and extensive onycholysis). In some cases, surgical therapies may need to be considered in addition to, or in preference to, topical nail lacquer treatment. The use of ciclopirox nail lacquer solution 8% as an adjunct to oral antifungal therapy may widen the spectrum of activity of the combination because of the broad spectrum of coverage provided by the lacquer. The use of combination therapy may be synergistic in terms of efficacy, enabling a reduction in the duration and cumulative dosage of oral therapy. This could result in a decrease in the frequency and severity of systemic adverse effects associated with the oral antimycotics and the need to be vigilant about drug interactions. Studies need to be conducted to determine the place of combination oral and topical lacquer therapy in the management of onychomycosis.
authors.affiliation: Department of Medicine, Sunnybrook and Women's College Health Sciences Center, and University of Toronto, Ontario, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: R
authors.initials: R
authors.lastname: Baran
mesh_terms: D000287:Administration, Topical; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077768:Ciclopirox; D005533:Foot Dermatoses / Q000188:drug therapy*; D005544:Forecasting; D006801:Humans; D014009:Onychomycosis / Q000145:classification / Q000188:drug therapy*; D019999:Pharmaceutical Solutions / Q000627:therapeutic use; D011379:Prognosis; D011728:Pyridones / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000935:Antifungal Agents; D019999:Pharmaceutical Solutions; D011728:Pyridones; D000077768:Ciclopirox